Of clinical relevance, pharmacological activation of AMPK is considered a potential therapeutic strategy for MASLD [81], while AMPK activation also increases HuR nuclear localization [54]. Here, ELAVL1 is linked to metabolic dysfunction-associated steatotic liver disease.